Quest Diagnostics (NYSE:DGX) Issues FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 9.550-9.800 for the period, compared to the consensus estimate of 9.720. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.7 billion.

Wall Street Analyst Weigh In

DGX has been the subject of several research reports. Barclays lifted their price target on shares of Quest Diagnostics from $154.00 to $168.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 23rd. Leerink Partners raised shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $169.00 to $174.00 in a research report on Monday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $185.00 price target (up previously from $175.00) on shares of Quest Diagnostics in a research report on Tuesday, December 10th. Piper Sandler boosted their price objective on Quest Diagnostics from $150.00 to $165.00 and gave the stock a “neutral” rating in a report on Monday, October 28th. Finally, Truist Financial increased their price objective on Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus price target of $172.15.

Quest Diagnostics Stock Performance

NYSE DGX traded up $7.91 during trading hours on Thursday, reaching $163.35. 602,388 shares of the company were exchanged, compared to its average volume of 909,599. The stock has a market capitalization of $18.23 billion, a P/E ratio of 21.98, a P/E/G ratio of 2.36 and a beta of 0.90. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. Quest Diagnostics has a 1 year low of $123.04 and a 1 year high of $167.08. The business’s 50 day simple moving average is $155.54 and its 200-day simple moving average is $153.42.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. On average, equities research analysts expect that Quest Diagnostics will post 8.9 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 21st. Stockholders of record on Monday, April 7th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.96%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.75. Quest Diagnostics’s dividend payout ratio is currently 40.32%.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the sale, the chief accounting officer now owns 34,941 shares of the company’s stock, valued at $5,382,661.05. The trade was a 34.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.79% of the stock is owned by corporate insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.